{"id":35300,"date":"2025-06-16T21:38:36","date_gmt":"2025-06-16T13:38:36","guid":{"rendered":"https:\/\/flcube.com\/?p=35300"},"modified":"2025-06-16T21:38:37","modified_gmt":"2025-06-16T13:38:37","slug":"changchun-high-tech-subsidiary-gains-nmpa-approval-for-cinv-drug-trial","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=35300","title":{"rendered":"Changchun High-Tech Subsidiary Gains NMPA Approval for CINV Drug Trial"},"content":{"rendered":"\n<p>China-based Changchun High &amp; New Technology Industries (Group) Inc. (<a href=\"https:\/\/www.google.com\/finance\/quote\/000661:SHE\">SHE: 000661<\/a>) announced that its subsidiary Changchun GeneScience Pharmaceutical Co., Ltd. has received clinical approval from the National Medical Products Administration (NMPA) to test its megestrol for the prevention of chemotherapy-induced nausea and vomiting (CINV). The drug was developed by Twi Pharmaceuticals, Inc.<\/p>\n\n\n\n<p><strong>Collaboration with Twi Pharmaceuticals<\/strong><\/p>\n\n\n\n<p>GeneScience entered into a partnership with the Taiwan &#8211; based Twi Pharmaceuticals in 2024, becoming the sole general agent of the drug in mainland China, Hong Kong, Macau, and Singapore. Previously, megestrol was approved for cancer-related anorexia-cachexia syndrome.<\/p>\n\n\n\n<p><strong>Drug Features and Advantages<\/strong><\/p>\n\n\n\n<p>Megestrol, the first nanocrystalline oral suspension formulation approved in mainland China, offers superior solubility and bioavailability compared to traditional solid dosage forms. Its food-independent pharmacokinetic profile provides added convenience. The drug works synergistically through multiple mechanisms of action to prevent CINV and has demonstrated efficacy and safety in multiple clinical studies. It is also included in the CSCO clinical guidelines.<\/p>\n\n\n\n<p><strong>Significance of the Approval<\/strong><\/p>\n\n\n\n<p>The approval marks a significant step forward for Changchun High-Tech and GeneScience in expanding their presence in the oncology support care market. With the growing demand for effective CINV prevention therapies, megestrol has the potential to address an important unmet need for patients undergoing chemotherapy.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/\u957f\u6625\u9ad8\u65b0\uff1a\u5173\u4e8e\u918b\u9178\u7532\u5730\u5b55\u916e\u53e3\u670d\u6df7\u60ac\u6db2\uff08\u7f8e\u9002\u4e9a\uff09\u836f\u7269\u4e34\u5e8a\u8bd5\u9a8c\u7533\u8bf7\u83b7\u5f97\u6279\u51c6\u7684\u516c\u544a.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of \u957f\u6625\u9ad8\u65b0\uff1a\u5173\u4e8e\u918b\u9178\u7532\u5730\u5b55\u916e\u53e3\u670d\u6df7\u60ac\u6db2\uff08\u7f8e\u9002\u4e9a\uff09\u836f\u7269\u4e34\u5e8a\u8bd5\u9a8c\u7533\u8bf7\u83b7\u5f97\u6279\u51c6\u7684\u516c\u544a.\"><\/object><a id=\"wp-block-file--media-757b838c-5452-4cd9-877f-148cff83c1c3\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/\u957f\u6625\u9ad8\u65b0\uff1a\u5173\u4e8e\u918b\u9178\u7532\u5730\u5b55\u916e\u53e3\u670d\u6df7\u60ac\u6db2\uff08\u7f8e\u9002\u4e9a\uff09\u836f\u7269\u4e34\u5e8a\u8bd5\u9a8c\u7533\u8bf7\u83b7\u5f97\u6279\u51c6\u7684\u516c\u544a.pdf\">\u957f\u6625\u9ad8\u65b0\uff1a\u5173\u4e8e\u918b\u9178\u7532\u5730\u5b55\u916e\u53e3\u670d\u6df7\u60ac\u6db2\uff08\u7f8e\u9002\u4e9a\uff09\u836f\u7269\u4e34\u5e8a\u8bd5\u9a8c\u7533\u8bf7\u83b7\u5f97\u6279\u51c6\u7684\u516c\u544a<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/\u957f\u6625\u9ad8\u65b0\uff1a\u5173\u4e8e\u918b\u9178\u7532\u5730\u5b55\u916e\u53e3\u670d\u6df7\u60ac\u6db2\uff08\u7f8e\u9002\u4e9a\uff09\u836f\u7269\u4e34\u5e8a\u8bd5\u9a8c\u7533\u8bf7\u83b7\u5f97\u6279\u51c6\u7684\u516c\u544a.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-757b838c-5452-4cd9-877f-148cff83c1c3\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>China-based Changchun High &amp; New Technology Industries (Group) Inc. (SHE: 000661) announced that its subsidiary&#8230;<\/p>\n","protected":false},"author":1,"featured_media":35302,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[2929,62,358,1171],"class_list":["post-35300","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-changchun-high-new-technology-industries","tag-clinical-trial-approval-initiation","tag-genescience-pharmaceutical","tag-she-000661"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Changchun High-Tech Subsidiary Gains NMPA Approval for CINV Drug Trial - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based Changchun High &amp; New Technology Industries (Group) Inc. (SHE: 000661) announced that its subsidiary Changchun GeneScience Pharmaceutical Co., Ltd. has received clinical approval from the National Medical Products Administration (NMPA) to test its megestrol for the prevention of chemotherapy-induced nausea and vomiting (CINV). The drug was developed by Twi Pharmaceuticals, Inc.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=35300\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Changchun High-Tech Subsidiary Gains NMPA Approval for CINV Drug Trial\" \/>\n<meta property=\"og:description\" content=\"China-based Changchun High &amp; New Technology Industries (Group) Inc. (SHE: 000661) announced that its subsidiary Changchun GeneScience Pharmaceutical Co., Ltd. has received clinical approval from the National Medical Products Administration (NMPA) to test its megestrol for the prevention of chemotherapy-induced nausea and vomiting (CINV). The drug was developed by Twi Pharmaceuticals, Inc.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=35300\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-06-16T13:38:36+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-06-16T13:38:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/1601-1.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35300#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35300\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Changchun High-Tech Subsidiary Gains NMPA Approval for CINV Drug Trial\",\"datePublished\":\"2025-06-16T13:38:36+00:00\",\"dateModified\":\"2025-06-16T13:38:37+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35300\"},\"wordCount\":220,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35300#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/1601-1.webp\",\"keywords\":[\"Changchun High &amp; New Technology Industries\",\"Clinical trial approval \\\/ initiation\",\"GeneScience Pharmaceutical\",\"SHE: 000661\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=35300#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35300\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=35300\",\"name\":\"Changchun High-Tech Subsidiary Gains NMPA Approval for CINV Drug Trial - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35300#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35300#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/1601-1.webp\",\"datePublished\":\"2025-06-16T13:38:36+00:00\",\"dateModified\":\"2025-06-16T13:38:37+00:00\",\"description\":\"China-based Changchun High & New Technology Industries (Group) Inc. (SHE: 000661) announced that its subsidiary Changchun GeneScience Pharmaceutical Co., Ltd. has received clinical approval from the National Medical Products Administration (NMPA) to test its megestrol for the prevention of chemotherapy-induced nausea and vomiting (CINV). The drug was developed by Twi Pharmaceuticals, Inc.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35300#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=35300\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35300#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/1601-1.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/1601-1.webp\",\"width\":1080,\"height\":608,\"caption\":\"Changchun High-Tech Subsidiary Gains NMPA Approval for CINV Drug Trial\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35300#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Changchun High-Tech Subsidiary Gains NMPA Approval for CINV Drug Trial\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Changchun High-Tech Subsidiary Gains NMPA Approval for CINV Drug Trial - Insight, China&#039;s Pharmaceutical Industry","description":"China-based Changchun High & New Technology Industries (Group) Inc. (SHE: 000661) announced that its subsidiary Changchun GeneScience Pharmaceutical Co., Ltd. has received clinical approval from the National Medical Products Administration (NMPA) to test its megestrol for the prevention of chemotherapy-induced nausea and vomiting (CINV). The drug was developed by Twi Pharmaceuticals, Inc.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=35300","og_locale":"en_US","og_type":"article","og_title":"Changchun High-Tech Subsidiary Gains NMPA Approval for CINV Drug Trial","og_description":"China-based Changchun High & New Technology Industries (Group) Inc. (SHE: 000661) announced that its subsidiary Changchun GeneScience Pharmaceutical Co., Ltd. has received clinical approval from the National Medical Products Administration (NMPA) to test its megestrol for the prevention of chemotherapy-induced nausea and vomiting (CINV). The drug was developed by Twi Pharmaceuticals, Inc.","og_url":"https:\/\/flcube.com\/?p=35300","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-06-16T13:38:36+00:00","article_modified_time":"2025-06-16T13:38:37+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/1601-1.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=35300#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=35300"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Changchun High-Tech Subsidiary Gains NMPA Approval for CINV Drug Trial","datePublished":"2025-06-16T13:38:36+00:00","dateModified":"2025-06-16T13:38:37+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=35300"},"wordCount":220,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=35300#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/1601-1.webp","keywords":["Changchun High &amp; New Technology Industries","Clinical trial approval \/ initiation","GeneScience Pharmaceutical","SHE: 000661"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=35300#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=35300","url":"https:\/\/flcube.com\/?p=35300","name":"Changchun High-Tech Subsidiary Gains NMPA Approval for CINV Drug Trial - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=35300#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=35300#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/1601-1.webp","datePublished":"2025-06-16T13:38:36+00:00","dateModified":"2025-06-16T13:38:37+00:00","description":"China-based Changchun High & New Technology Industries (Group) Inc. (SHE: 000661) announced that its subsidiary Changchun GeneScience Pharmaceutical Co., Ltd. has received clinical approval from the National Medical Products Administration (NMPA) to test its megestrol for the prevention of chemotherapy-induced nausea and vomiting (CINV). The drug was developed by Twi Pharmaceuticals, Inc.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=35300#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=35300"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=35300#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/1601-1.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/1601-1.webp","width":1080,"height":608,"caption":"Changchun High-Tech Subsidiary Gains NMPA Approval for CINV Drug Trial"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=35300#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Changchun High-Tech Subsidiary Gains NMPA Approval for CINV Drug Trial"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/1601-1.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/35300","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=35300"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/35300\/revisions"}],"predecessor-version":[{"id":35303,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/35300\/revisions\/35303"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/35302"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=35300"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=35300"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=35300"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}